Therapies
Read more about Low Dose Naltrexone
About Us
Discover Immune Therapeutics
Investors
Investor data
News
Read the latest news

LDN (low dose naltrexone)

Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications, is currently used as an immune modulator.

MENK

OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.

0 26 July 2016

ORLANDO, FL–(Marketwired – Jul 26, 2016) – Immune Therapeutics, Inc. (OTCQB: IMUN) An Informational Shareholder Meeting will be held on Wednesday, August 17, 2016, at 10 a.m. EDT, at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, FL 32801.

Posted in Press Releases by admin
0 16 June 2016

ORLANDO, Fla., June 15, 2016 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, today announced that it has retained Maxim Group LLC, a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services to the company. Maxim will focus on strategies to maximize shareholder value through its full scope of investment banking services.

“Engaging Maxim is paramount in the company’s maturation that will enable the strategic positioning of Immune Therapeutics for investors and, in turn, increase its capacity to reach as many people who will benefit from its proprietary immune therapy,” said Immune Therapeutics Chief Executive Officer, Noreen Griffin.

Posted in Press Releases by admin
0 19 May 2016

ORLANDO, Fla., May 19, 2016 /PRNewswire/ — Immune Therapeutics, Inc. (O
TCQB: IMUN ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly ( ” WHA ” ) in Geneva, Switzerland to promote Lodonal™.

The WHA is the decision-making body of the World Health Organization (“WHO”). It is attended by delegations from all WHO member states and focuses on a specific health agenda prepared by the executive board. The main functions of the WHA are to determine the policies of the organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget (www.who.int/mediacentre/events/2016/wha69/en/).

Posted in Press Releases by admin
Load More